Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,664.00
(
0.21%
)
News Focus
News Focus
Post# of 257266
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 123628

Wednesday, 07/20/2011 8:02:20 AM

Wednesday, July 20, 2011 8:02:20 AM

Post# of 257266
In other words, Neugranin does not infringe on AMGN’s Neulasta patents, but it does infringe on AMGN’s Neupogen patents; thus, it makes sense that the AMGN-Teva settlement calls for Neugranin to be launched when the Neupogen patents expire in Nov 2013.

Do you agree with the inference in the bottom paragraph of #msg-65308970, i.e. that the Neulasta knockoff from Ratiopharm will not be brought to market in the US?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today